EUVIMEDEUVIMED entdecken
VergleichsstudieStudienprotokoll

Clinical outcomes of modified post‐transplantation cyclophosphamide versus granulocyte colony‐stimulating factor/anti‐thymocyte globulin‐based protocol in alternative donor transplantation for severe aplastic anaemia

Liangliang Wu iD, Ming Zhou, Xiaowei Chen, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Caixia Wang, Shilin Xu, Fangfang Yang, Yuling Zhang, Xiaoqing He, Xinxin Li und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70133 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Liangliang Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Blood Transfusion and Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, …. Hauptthemen laut MEDLINE: Cyclophosphamide, Anemia, Aplastic, Antilymphocyte Serum, Granulocyte Colony-Stimulating Factor. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Key R&D program of China, 2019 Annual Research Project of The China Marrow Donor Program, Guangzhou General Science and Technology Project of Health and Family Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post‐transplantation cyclophosphamide (PTCy) and granulocyte colony‐stimulating factor/anti‐thymocyte globulin (G‐CSF/ATG) are established protocols for alternative donor haematopoietic stem cell transplantation (AD‐HSCT) in severe aplastic anaemia (SAA). A modified PTCy (mPTCy) regimen, featuring increased ATG dosing (2.0 mg/kg/day, days −5 to −3) and reduced cyclophosphamide (40 mg/kg/day, days +3 and +4), showed promising outcomes in a prospective study but lacks direct comparison with G‐CSF/ATG. This post hoc comparative analysis utilized data from our prospective mPTCy cohort (ChiCTR2000038297, n = 101, plus a 1‐year protocol‐consistent enrolment extension, n = 56) and a retrospective historical G‐CSF/ATG cohort ( n = 140) to compare outcomes in AD‐HSCT. Both protocols showed similar incidences of engraftment, graft failure and overall survival. Multivariate analysis confirmed reduced risks of 100‐day grade II–IV acute graft‐versus‐host disease (GVHD) (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.26–0.71, p < 0.001) and 2‐year chronic GVHD (HR 0.33, 95% CI 0.17–0.65, p = 0.001), and improved 2‐year GVHD, relapse/rejection‐free survival (GRFS; HR 0.51, 95% CI 0.32–0.83, p = 0.007) with mPTCy versus G‐CSF/ATG. Subgroup analysis revealed superior outcomes with mPTCy in haploidentical‐HSCT, while outcomes were comparable between protocols in unrelated donor HSCT. These findings suggest mPTCy superiority over G‐CSF/ATG in SAA patients undergoing AD‐HSCT, especially haploidentical‐HSCT, by reducing GVHD and improving GRFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideAnemia, AplasticAntilymphocyte SerumGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHumansFemaleMaleAdultMiddle AgedAdolescentGraft vs Host DiseaseTreatment OutcomeYoung AdultChildRetrospective StudiesTransplantation ConditioningChild, PreschoolProspective Studies

Stichwörter der Autor:innen

AD‐HSCTG‐CSF/ATGSAAmPTCy

Substanzen

CyclophosphamideAntilymphocyte SerumGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Hematology, Institute of Blood Transfusion and Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.

ORCID-Profile: Liangliang Wu, Shunqing Wang, Yuping Zhang

Förderung

  • National Key R&D program of China
  • 2019 Annual Research Project of The China Marrow Donor Program
  • Guangzhou General Science and Technology Project of Health and Family Planning
  • Innovative Clinical Technique of Guangzhou
  • Guangzhou Municipal Science and Technology Project
  • National Key Research and Development Program of China

Zitieren

APA

Wu, L., Zhou, M., Chen, X., Mo, W., Zhou, R., Li, Y., Wang, C., Xu, S., Yang, F., Zhang, Y., He, X., Li, X., Wang, S., & Zhang, Y. (2025). Clinical outcomes of modified post‐transplantation cyclophosphamide versus granulocyte colony‐stimulating factor/anti‐thymocyte globulin‐based protocol in alternative donor transplantation for severe aplastic anaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70133

Vancouver

Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, et al. Clinical outcomes of modified post‐transplantation cyclophosphamide versus granulocyte colony‐stimulating factor/anti‐thymocyte globulin‐based protocol in alternative donor transplantation for severe aplastic anaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.70133

BibTeX
@article{Wu2025,
  author = {Wu, Liangliang and Zhou, Ming and Chen, Xiaowei and Mo, Wenjian and Zhou, Ruiqing and Li, Yumiao and Wang, Caixia and Xu, Shilin and Yang, Fangfang and Zhang, Yuling and He, Xiaoqing and Li, Xinxin and Wang, Shunqing and Zhang, Yuping},
  title = {Clinical outcomes of modified post‐transplantation cyclophosphamide versus granulocyte colony‐stimulating factor/anti‐thymocyte globulin‐based protocol in alternative donor transplantation for severe aplastic anaemia},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70133}
}
Kostenlos starten →